ORACLE Study Explores Efficacy of Post-Combination Therapies in Non-Clear Cell RCC - Deepak Kilari
Deepak Kilari
Zachary Klaassen speaks with Deepak Kilari about the ORACLE study examining subsequent treatments after combination therapy in non-clear cell renal cell carcinoma.
Combination HIF-2α/VEGF Dual Inhibition in Refractory Clear Cell RCC - Michael Serzan
Pedro Barata discusses kidney cancer data with Michael Serzan regarding the combination of Casdatifan (AB-521), a HIF-2 alpha inhibitor, with cabozantinib for treatment-refractory clear cell RCC.
